Other routes would require different dosing entirely due to varying bioavailability
Bhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, et al
Taken together, the GLP-1 experience illustrates both the promise and the limits of peptide pharmacology
While mild constipation on semaglutide can often be managed with over-the-counter measures, certain symptoms warrant prompt medical evaluation
Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk, said: "Based on the significant unmet need in Alzheimer's disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide's potential, despite a low likelihood of success